Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.35 |
| ▸ | ACHE | P22303 | 3/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.33 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.33 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.33 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.33 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.33 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22828510 | 0.96 | KMT2A (0.44) | KMT2AL3MBTL1HRH3ACHETSHR | |
| SCHEMBL11919044 | 0.96 | KMT2A (0.47) | KMT2ASMN1; SMN2HRH3ACHETSHR | |
| SCHEMBL23384251 | 0.94 | KMT2A (0.43) | KMT2AL3MBTL1HRH3ACHETSHR | |
| SCHEMBL25123775 | 0.89 | KMT2A (0.40) | KMT2AL3MBTL1HRH3ACHETLR9 | |
| SCHEMBL12325469 | 0.85 | KMT2A (0.39) | KMT2ASMN1; SMN2HRH3TSHR | |
| SCHEMBL11919058 | 0.83 | KMT2A (0.56) | KMT2ASMN1; SMN2ACHECHRM4OPRM1 | |
| SCHEMBL22456342 | 0.83 | HRH3 (0.41) | L3MBTL1HRH3TSHRTLR9TLR8 | |
| SCHEMBL14453902 | 0.83 | HRH3 (0.41) | L3MBTL1HRH3TSHRTLR9TLR8 | |
| SCHEMBL11919045 | 0.83 | KMT2A (0.56) | KMT2ASMN1; SMN2ACHECHRM4 | |
| SCHEMBL26171322 | 0.83 | PIK3CD (0.36) | KMT2AHRH3TLR9TLR8TLR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210147385-A1 | COMPOUNDS AND METHODS FOR TARGETING PATHOGENIC BLOOD VESSELS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2021-05-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210147385-A1 | COMPOUNDS AND METHODS FOR TARGETING PATHOGENIC BLOOD VESSELS | TEK, KDR, LIPG | KMT2A 4795/4885SMN1; SMN2 1703/4885L3MBTL1 2745/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.